ARTICLE
1 April 2026

Canada Announces New Pharmaceutical And Life Sciences Sector Task Force

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation...
Canada Food, Drugs, Healthcare, Life Sciences
Urszula Wojtyra’s articles from Smart & Biggar are most popular:
  • within Food, Drugs, Healthcare and Life Sciences topic(s)
  • in Canada

On March 18, 2026, the federal Minister of Health announced the creation of the Pharmaceutical and Life Sciences Sector Task Force, a joint initiative led by Health Canada and Innovation, Science and Economic Development Canada. The Task Force will include members from various stakeholder groups, including pharmaceutical representatives and biotechnology firms. According to the announcement, the "Task Force will explore innovative, made-in-Canada solutions that enhance competitiveness, and long-term growth to support reliable and sustainable access to pharmaceutical products in Canada" and will build on Health Canada's "Red Tape Review" seeking to reduce unnecessary regulatory burden by modernizing regulatory frameworks.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group or the Pharmaceutical Litigation Group.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More